Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: Results from the nationwide Danish DANBIO database [2]

Scandinavian Journal of Rheumatology

Volumn 36, Issue 2, 2007, Pages 151-154

  Ostergaard M ^a,b,c,i   Unkerskov, J ^d   Linde, L ^a   Krogh, N S ^e   Ravn, T ^d   Ringsdal, V S ^f   Petri, A ^b,c   Andersen, L S ^g   Tarp, U ^h   Hansen, A ^b,c   Hjardem, E ^a   Hetland, M L ^a,b,c  

^a Danish Database for Biological Therapies in Rheumatology (DANBIO)   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Rigshospitalet   (Denmark)

^d Inst for Rational Pharmacotherapy   (Denmark)

^e Zitelab   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

BIOLOGICAL THERAPY; DATA BASE; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DENMARK; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIERS ESTIMATE; METHOTREXATE; PATIENT COMPLIANCE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247558725     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740601089267     Document Type: Letter

References (7)

1. van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum 2003;48:1500-3.
2. van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003;5:R347-51.
3. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
4. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
5. Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005;34:40-4.
6. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
7. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.